DE1795590A1 - New 7-amino-cephalosporanic acid esters - Google Patents
New 7-amino-cephalosporanic acid estersInfo
- Publication number
- DE1795590A1 DE1795590A1 DE19641795590 DE1795590A DE1795590A1 DE 1795590 A1 DE1795590 A1 DE 1795590A1 DE 19641795590 DE19641795590 DE 19641795590 DE 1795590 A DE1795590 A DE 1795590A DE 1795590 A1 DE1795590 A1 DE 1795590A1
- Authority
- DE
- Germany
- Prior art keywords
- amino
- new
- acid esters
- cephalosporanic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/18—7-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41F—PRINTING MACHINES OR PRESSES
- B41F17/00—Printing apparatus or machines of special types or for particular purposes, not otherwise provided for
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C3/00—Packages of films for inserting into cameras, e.g. roll-films, film-packs; Wrapping materials for light-sensitive plates, films or papers, e.g. materials characterised by the use of special dyes, printing inks, adhesives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
Description
Case 5.259/1-Vb 'Case 5.259 / 1-Vb '
DeutschlandGermany
Neue 7-Amino-cephalosporansaureester.New 7-amino-cephalosporanic acid esters.
Die-Herstellung von 7-Amino-cephalosporansäureestern g mit freier Äminogruppe aus Cephalosporin C bot bisher erheb- ■ erhebliche Schwierigkeiteni da die Amidgruppe des ß-Lactamringes gegenüber hydrolysierenden Agentien viel empfindlicher ist als die Amidgruppe in 7-Stellung, in der deutschen Anmeldung P 14 45 619.O-44 (5259/1-4) ist ein neues Verfahren zur Herstellung von 7-Amino-cephalosporansäureestern besehrieben.The production of 7-amino-cephalosporanic acid esters g with a free amino group from cephalosporin C has presented considerable difficulties so far because the amide group of the ß-lactam ring is much more sensitive to hydrolyzing agents than the amide group in the 7-position, in the German application P 14 45 619.O-44 (5259 / 1-4) describes a new process for the preparation of 7-amino-cephalosporanic acid esters.
Gegenstand der vorliegenden Teilanmeldung sind neue 7-Amino-cephalosporansäureester, nämlich Ester, deren Alkohol-The present divisional application relates to new 7-amino-cephalosporanic acid esters, namely esters whose alcohol
OFtIGiNALOFTIGiNAL
2 09812/17402 09812/1740
komponente Benzhydrol oder ρ,ρ-Dimethoxybenzhydrol ist. Diese Ester können nach dem in der genannten Anmeldung beschriebenen Verfahren hergestellt werden.component is benzhydrol or ρ, ρ-dimethoxybenzhydrol. These Esters can be prepared by the process described in the application mentioned.
Die Ester können durch Hydrolyse in die freie 7-Aminocephalosporansäure übergeführt werden, vorzugsweise mittels Trifluoressigsäure' und Anisol.The esters can be converted into the free 7-aminocephalosporanic acid by hydrolysis be converted, preferably by means of trifluoroacetic acid 'and anisole.
Die Erfindung wird in dem nachfolgenden Beispiel beschrieben. Die Temperaturen sind in Gelsiusgraden angegeben.The invention is described in the following example. The temperatures are given in degrees Celsius.
2 0 9812/1740 BAD ORIGINAL2 0 9812/1740 BAD ORIGINAL
12,6 g Cephalosporin C-di-benzhydrylester werden -in 2 Liter abs. Methylenchlorid gelöst, mit 2 ml 2-n. wässriger 'Essigsäure versetzt und 8 Tage bei 22 im Dunkeln stehen gelassen. Man dampft im Vakuum ein und nimmt den.-. Rückstand in einem Gemisch von 5 Teilen Toluol, 2 Teilen '' Essigester, 3 Teilen Alkohol und 3 Teilen 2-n.' wässriger Salzsäure auf. Nach vollständiger Lösung bei kräftigem Schütteln werden die Phasen getrennt und die Ünterphase mit zwei weiteren Oberphasen (5 Teile Toluol und 2 Teile r Essigester) ausgeschüttelt. Die 3 Oberphasen werden noch ^mal mit' Alkohol-2-n. Salzsäure (l:l) nachextrahiert. Die produkthaltigen Unterphasen werden vereinigt, mit 50-proz.12.6 g of Cephalosporin C-di-benzhydryl ester are -in 2 liters of abs. Dissolved methylene chloride, with 2 ml of 2-n. aqueous' acetic acid and left to stand for 8 days at 22 in the dark. It is evaporated in a vacuum and takes the.-. Residue in a mixture of 5 parts of toluene, 2 parts of '' ethyl acetate, 3 parts of alcohol and 3 parts of 2-n. ' aqueous hydrochloric acid. After complete dissolution, with vigorous shaking, the phases are separated and the Ünterphase with two other top phase (r 5 parts toluene and 2 parts Essigester) extracted. The 3 upper phases are again ^ times with 'alcohol-2-n. Hydrochloric acid (l: l) extracted. The product-containing sub-phases are combined with 50 percent.
wässriger Trikaliumphosphatlosung auf pH 6. gestellt und im Vakuum vom Alkohol befr'eit. Hierauf stellt man mit der (j Trikaliumphosphatlosung auf pH 8,0 und extrahiert ~$maX mit Essigester. Der über Natriumsulfat getrocknete Extrakt gibt beim Eindampfen den Y-Amino-cephalosporansäure-benzhydrylester, der aus Aether in zu Drusen vereinigten ' Nadeln kristallisiert; P. 122-124°; er zeigt im Dünn- . schichtchromatogramm an Silicagel im System.n-ButänolrEisessig (10:1) gesättigt mit V/asser einen Rf-Wert von 0,64 (schmutziggelber Pleck mit Ninhydrin-Collidin)Λaqueous tripotassium phosphate solution adjusted to pH 6 and freed from alcohol in vacuo. Then one introduces the (j Trikaliumphosphatlosung to pH 8.0 and extracted with ~ $ max Essigester The dried over sodium sulfate, the extract is by evaporation of the Y-amino-cephalosporanic acid benzhydryl ester, which combined from ether to drusen in 'needles crystallized. P 122-124 °; in the thin-layer chromatogram on silica gel in the system, n-butanol r glacial acetic acid (10: 1) saturated with water / water an Rf value of 0.64 (dirty yellow spot with ninhydrin-collidine) Λ
2098 12/17 402098 12/17 40
■·. Der Ester kann wie folgt in die freie 7-Aminoeephalo-.sporansäure übergeführt werden :_ man löst 6,8 g = 1 Teil Ester . in 1 Teil Anisol und versetzt mit 5 Teilen Trifluoressigsäure. Man dampft anschliessend sofort bei 0,2 mm Quecksilbersäule.■ ·. The ester can be converted into the free 7-aminoeephalo-sporic acid as follows: 6.8 g = 1 part of ester is dissolved. in 1 part of anisole and mixed with 5 parts of trifluoroacetic acid. You then immediately vaporize at 0.2 mm of mercury.
'innerhalb,20 Hinuten'ein, nimmt in JO ml Essigester auf und giesst die Lösung gleichzeitig mit ca. I3 ml 50-proz. wässriger Trikaliumphosphatlösung unter Rühren auf 20 ml-3-proz. wässrige- Dikaliumhydrogenphosphatlösung. Die beiden Zuflüsse sind dabei so .zu bemessen, dass das pH zwischen 6-8 pendelt und am Ende .auf 7 stehen bleibt. Die abgetrennte wässrige Phase wird noch 2mal-mit · je 10 mi/'Essigester·. ■"·' und die 3 Essigesterphasen werden 2mal mit je 5 ml j5-proz«. wässriger Dikaliumhydrogenphosphatlösung gewaschen. Man verwirft die organischen Phasen, vereinigt die wässrigen und stellt mit ca. k ml konz. Salzsäure auf pH 3,5.. Das' nach 15 Std. Stehen bei'0 abgeschiedene Produkt wird abfiltrlert, mit wenig Eiswasser gewaschen und getrocknet. Man erhält 3,90 g (= 92% d.Th.) reine 7-Amino-cephalosporansäure. 'within, 20 minutes' one, takes up ml of ethyl acetate in JO and pours the solution at the same time with approx. 13 ml of 50 percent. aqueous tripotassium phosphate solution with stirring to 20 ml-3 percent. aqueous dipotassium hydrogen phosphate solution. The two inflows are to be measured in such a way that the pH fluctuates between 6-8 and at the end of the day stays at 7. The separated aqueous phase is mixed twice with 10 ml / 'ethyl acetate each time. ■ "* 'and the 3 Essigesterphasen are washed 2 times with 5 ml j5-proz." Aqueous dipotassium hydrogen phosphate solution. It discards the organic phases are pooled, the aqueous and provides approximately k ml of conc. Hydrochloric acid to pH 3.5 .. The The product deposited after 15 hours of standing at 0 is filtered off, washed with a little ice water and dried, giving 3.90 g (= 92% of theory) of pure 7-amino-cephalosporanic acid.
209812/mO ' BADOWaiH«.209812 / mO 'BADOWaiH «.
Der als Ausgangsmaterial·verwendete Cephalosporin C-di-benzhydrylester kann wie folgt hergestellt werden:The cephalosporin C-di-benzhydryl ester used as starting material can be prepared as follows:
Eine Suspension von 4,82 g 85 $igem Cephalosporin C-Natriumsalz (♦ 2 HpO; 8,7 mMol) in 80 ml Methanol wird mit ΐβ,7 ml 1,5 n.-methanolischer Salzsäure versetzt und die klare Lösung bei 0,1 mm Hg eingedampft. Der Rückstand enthält rohes Cephalosporin G-hydrdchlorid, dass anschliessend I in 100 ml Dimethylformamid gelöst und mit 10 g Diphenyldiazome.than· 20 Minuten bei 20° verestert wird. Eindampfen, Digerieren mit Petroläther, Aufnehman in Essigester, Waschen.mit 10 Dikaliumphosphatlösung, Trocknen über Natriumsulfat und . Eindampfen im Vakuum ergibt 7,26 g (ca. 70 ^igen) Cephalosporin C-dibenzhydrylester als farblosen Schaum. Die Verbindung zeigt im Dünnschichtchromatogramm an Silicagel G folgende Rf-Werte: 0,65 im System n-Butanol-Eisessig(10:l) gesättigt mit Wasser; 0,78 im System n-Butanol-Pyridin-Eisessig-Was-' ser (38:24:8:30); 0,12 im System Toluol-Aceton (7:3); typisch rotvioletter Fleck mit Ninhydrin-Collidin. pK ^=6,35. * MCSA suspension of 4.82 g of 85% cephalosporin C sodium salt (♦ 2 HpO; 8.7 mmol) in 80 ml of methanol is mixed with ΐβ, 7 ml of 1.5 N-methanolic hydrochloric acid and the clear solution at 0. 1 mm Hg evaporated. The residue contains crude cephalosporin G hydrochloride that is then dissolved in 100 ml of dimethylformamide and esterified with 10 g of diphenyldiazome.thane for 20 minutes at 20 °. Evaporation, digestion with petroleum ether, absorption in ethyl acetate, washing with 10 dipotassium phosphate solution, drying over sodium sulfate and. Evaporation in vacuo gives 7.26 g (approx. 70%) of cephalosporin C-dibenzhydryl ester as a colorless foam. In the thin-layer chromatogram on silica gel G, the compound shows the following Rf values: 0.65 in the n-butanol-glacial acetic acid system (10: 1) saturated with water; 0.78 in the n-butanol-pyridine-glacial acetic acid-water system (38: 24: 8: 30); 0.12 in the toluene-acetone system (7: 3); typical red-violet spot with ninhydrin collidine. pK ^ = 6.35. * MCS
2 0 9812/17402 0 9812/1740
Claims (2)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH329363A CH447172A (en) | 1963-03-15 | 1963-03-15 | Process for the preparation of 7-amino-cephalosporanic acid esters |
CH329363 | 1963-03-15 | ||
CH406863 | 1963-03-29 | ||
CH406863 | 1963-03-29 | ||
CH492363 | 1963-04-19 | ||
CH492363 | 1963-04-19 | ||
CH126264 | 1964-02-04 | ||
CH126264 | 1964-02-04 | ||
BE645157A BE645157A (en) | 1963-03-15 | 1964-03-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
DE1795590A1 true DE1795590A1 (en) | 1972-03-16 |
DE1795590B2 DE1795590B2 (en) | 1975-09-18 |
DE1795590C3 DE1795590C3 (en) | 1976-04-29 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
NL145555B (en) | 1975-04-15 |
SE313813B (en) | 1969-08-25 |
DE1795590B2 (en) | 1975-09-18 |
BE645157A (en) | 1964-09-14 |
DE1445619A1 (en) | 1969-09-25 |
GB1027750A (en) | 1966-04-27 |
CH447172A (en) | 1967-11-30 |
NL6402678A (en) | 1964-09-16 |
DK118821B (en) | 1970-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2760156C2 (en) | ||
DE2760287C2 (en) | ||
DE1795590A1 (en) | New 7-amino-cephalosporanic acid esters | |
DE1795590C3 (en) | 7-Amino-cephalosporanic acid benzhydryl and p, p'-dimethoxybenzhydryl ester | |
DE1593315C (en) | ||
DE2436332A1 (en) | SUBSTITUTED TETRAHYDROFURANS AND PROCESS FOR THEIR PRODUCTION | |
AT261130B (en) | Process for the production of the new 3.2 Dioxo 17α methyl 19 nor pregna 4,9,11 triens | |
DE3219407C2 (en) | ||
DE1593315B1 (en) | 9-isopropylidene-9,10-dihydroanthracene-10-carboxylic acid-ß-diaethylamino-ethyl ester, their salts and process for their preparation | |
DE931947C (en) | Process for the preparation of 20, 21-pregnanketol esters | |
DE1618815B1 (en) | Process for the preparation of 3-oxogona-4,9,11-trienes | |
CH281597A (en) | Process for the production of an anhydro-corticosterone. | |
DE942926C (en) | Process for the production of 11ª ‡ -oxy-17ª ‡ -methyltestosterone or 11ª ‡ -oxy-10-normethyl-17ª ‡ -methyltestosterone | |
AT295056B (en) | Process for the production of the new 7α-methyl-3,16β, 17α-trihydroxy-Δ <1,3,5 (10)> - oestratriens | |
AT238382B (en) | Process for the preparation of 17α-acyloxy-6α-methyl-16-methylenepregn-4-en-3,20-dione | |
AT233174B (en) | Process for the preparation of 3-keto-Δ4, 6-10 (α) -methyl steroids | |
DE1643495C (en) | 4 (8 carboxyoctyl) 1,3 dithra cyclopentan 2 ones or 2 thiones and process for their preparation | |
DE1593807C (en) | alpha ascine methyl or ethy (ester, as well as a process for their production | |
DE1643018B2 (en) | 4-CHLORINE-1,2-ALPHA-METHYLENE-DELTA HIGH 4,6-PRGNADIEN-17-ALPHA-OL-3,20-DIONE AND ITS 17-ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THEM | |
AT247854B (en) | Process for the preparation of new substituted malonic acid monohydrazides and their salts | |
DE2508965C2 (en) | 1'-Desmethyl-1 '- (β-hydroxyethyl) -clindamycin-2-palmitate, its acid addition salts and process for their preparation | |
DE1618815C (en) | Process for the preparation of 3 oxogona 4,9,11 tons | |
AT233176B (en) | Process for the preparation of new 21-half esters of 3, 20-dioxo-21-hydroxypregnane compounds which are unsaturated in ring A | |
DE1029825B (en) | Process for the preparation of 19-nortestosterone hexahydrobenzoate | |
DE2022695A1 (en) | 21-phosphate pregnanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C3 | Grant after two publication steps (3rd publication) | ||
E77 | Valid patent as to the heymanns-index 1977 | ||
EHV | Ceased/renunciation |